Catalyst Event
CSPC Pharmaceutical Group Ltd (1093) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
4/29/2026, 12:00:00 AM
The company's antibody-drug conjugate (ADC) SYS6051 received approval from the US FDA on 2026-04-29 to commence clinical trials for advanced solid tumors, following a similar approval from China's NMPA in April 2026; Medium importance estimated due to the significant regulatory milestone, with positive impact expected.
Korean Translation
2026년 4월 29일에 자사의 항체-약물 접합체(ADC) SYS6051이 미국 FDA의 임상시험 개시 승인을 획득했으며(4월 중국 NMPA 승인에 이은 성과), 주요 규제 기관 승인에 따라 중간 수준의 긍정적 영향이 예상됨.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
On June 16, 2026, the Annual General Meeting 2026 is scheduled; low impact expected as it is a routine corporate event, scheduled.
6/16/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic is scheduled to report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026. This event is expected to have a medium impact as earnings reports typically drive significant price volatility scheduled.
6/3/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Earnings Release
On May 18, 2026, publication of the full-year results for the 2025/26 fiscal year is scheduled. The company expects growth to be at the lower end of guidance; high impact expected as earnings are a key market driver, expected.
5/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM